{"id":457352,"date":"2021-03-15T07:33:09","date_gmt":"2021-03-15T11:33:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457352"},"modified":"2021-03-15T07:33:09","modified_gmt":"2021-03-15T11:33:09","slug":"strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/","title":{"rendered":"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DUBLIN, Ireland and TREVOSE, Pa., March  15, 2021  (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at Oppenheimer\u2019s 31<sup>st<\/sup> Annual Healthcare Conference on Wednesday, March 17, at 10:00 a.m. ET.\u00a0\u00a0 The conference is being held virtually.<\/p>\n<p align=\"justify\">The Company\u2019s presentation will be webcast live and archived on the \u201cEvents &amp; Presentations\u201d page in the Investor section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BElilYmMWQsabQ6LpJNTsJuXAKVRKrgq9p-GF1Y_uSE__bTZ_u7wa9V93k2gjBonY0HFhB_tfX9xfCWR-rXaPw8lY5VMVfVU10AIX7sHLRI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.strongbridgebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Strongbridge Biopharma<br \/><\/strong>Strongbridge Biopharma\u00a0is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV<sup>\u00ae<\/sup> (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing\u2019s syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the\u00a0European Medicines Agency. The Company\u2019s rare neuromuscular franchise includes KEVEYIS<sup>\u00ae<\/sup> (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in\u00a0the\u00a0United States.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Solebury Trout<br \/>Mike Biega<br \/>+1 617-221-9660<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-JVauZyG0J9r-OYpVFuI_gIA8V8T8LVmUEb23VAqybM8SeQ0jri9aurX6U1TIxslEwrbnEkBSAC0iZdazRtSXkae6DQaBFtXeOrJK7HSCqs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mbiega@soleburytrout.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Corporate and Media Relations<\/strong><br \/>\n        <br \/>Elixir Health Public Relations<br \/>Lindsay Rocco<br \/>+1 862-596-1304<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GVukEQDy4APSgr4lSnHKFn1uC0n_8zlK6uVJd43Jn2fdw1_mSXUh93B5rnkS_QrBfM3Bims_2bvEcnSP9_3Uy5DYjl-DpntVtSVULOK_RYY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>lrocco@elixirhealthpr.com<\/u><\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e89863fa-c016-400d-8e68-ca14c363e961\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at Oppenheimer\u2019s 31st Annual Healthcare Conference on Wednesday, March 17, at 10:00 a.m. ET.\u00a0\u00a0 The conference is being held virtually. The Company\u2019s presentation will be webcast live and archived on the \u201cEvents &amp; Presentations\u201d page in the Investor section of the Company\u2019s website at\u00a0www.strongbridgebio.com. About\u00a0Strongbridge BiopharmaStrongbridge Biopharma\u00a0is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV\u00ae (levoketoconazole), a cortisol synthesis inhibitor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457352","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at Oppenheimer\u2019s 31st Annual Healthcare Conference on Wednesday, March 17, at 10:00 a.m. ET.\u00a0\u00a0 The conference is being held virtually. The Company\u2019s presentation will be webcast live and archived on the \u201cEvents &amp; Presentations\u201d page in the Investor section of the Company\u2019s website at\u00a0www.strongbridgebio.com. About\u00a0Strongbridge BiopharmaStrongbridge Biopharma\u00a0is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV\u00ae (levoketoconazole), a cortisol synthesis inhibitor &hellip; Continue reading &quot;Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T11:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference\",\"datePublished\":\"2021-03-15T11:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/\"},\"wordCount\":258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/\",\"name\":\"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=\",\"datePublished\":\"2021-03-15T11:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference - Market Newsdesk","og_description":"DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at Oppenheimer\u2019s 31st Annual Healthcare Conference on Wednesday, March 17, at 10:00 a.m. ET.\u00a0\u00a0 The conference is being held virtually. The Company\u2019s presentation will be webcast live and archived on the \u201cEvents &amp; Presentations\u201d page in the Investor section of the Company\u2019s website at\u00a0www.strongbridgebio.com. About\u00a0Strongbridge BiopharmaStrongbridge Biopharma\u00a0is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV\u00ae (levoketoconazole), a cortisol synthesis inhibitor &hellip; Continue reading \"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T11:33:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference","datePublished":"2021-03-15T11:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/"},"wordCount":258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/","name":"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=","datePublished":"2021-03-15T11:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTc4MCM0MDYzNDU1IzIwMjAwMjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-present-at-oppenheimers-31st-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Strongbridge Biopharma plc to Present at Oppenheimer\u2019s 31st Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457352"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457352\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}